Literature DB >> 28710906

Upward drift in cerebrospinal fluid amyloid β 42 assay values for more than 10 years.

Suzanne E Schindler1, Courtney L Sutphen1, Charlotte Teunissen2, Lena M McCue3, John C Morris1, David M Holtzman1, Sandra D Mulder2, Philip Scheltens4, Chengjie Xiong5, Anne M Fagan6.   

Abstract

INTRODUCTION: The best-established cerebrospinal fluid (CSF) biomarkers for Alzheimer's disease are levels of amyloid β 42 (Aβ42), total tau (tau), and phosphorylated tau 181 (ptau). We examined whether a widely used commercial immunoassay for CSF Aβ42, tau, and ptau provided stable measurements for more than ∼10 years.
METHODS: INNOTEST assay values for CSF Aβ42, tau, and ptau from Washington University in St. Louis and VU Medical Center, Amsterdam, were evaluated.
RESULTS: Aβ42 values as measured by the INNOTEST assay drifted upward by approximately 3% per year over the past decade. Tau values remained relatively stable, whereas results for ptau were mixed. DISCUSSION: Assay drift may reduce statistical power or even confound analyses. The drift in INNOTEST Aβ42 values may reduce diagnostic accuracy for Alzheimer's disease in the clinic. We recommend methods to account for assay drift in existing data sets and to reduce assay drift in future studies.
Copyright © 2017 the Alzheimer's Association. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Alzheimer disease; Amyloid; Assay drift; Biomarker; Cerebrospinal fluid; Cutoff; INNOTEST; Quality control

Mesh:

Substances:

Year:  2017        PMID: 28710906      PMCID: PMC5750131          DOI: 10.1016/j.jalz.2017.06.2264

Source DB:  PubMed          Journal:  Alzheimers Dement        ISSN: 1552-5260            Impact factor:   21.566


  27 in total

1.  Recommendations for the incorporation of biomarkers into Alzheimer clinical trials: an overview.

Authors:  John C Morris; Dennis J Selkoe
Journal:  Neurobiol Aging       Date:  2011-12       Impact factor: 4.673

2.  The clinical use of cerebrospinal fluid biomarker testing for Alzheimer's disease diagnosis: a consensus paper from the Alzheimer's Biomarkers Standardization Initiative.

Authors:  José Luis Molinuevo; Kaj Blennow; Bruno Dubois; Sebastiaan Engelborghs; Piotr Lewczuk; Armand Perret-Liaudet; Charlotte E Teunissen; Lucilla Parnetti
Journal:  Alzheimers Dement       Date:  2014-08-20       Impact factor: 21.566

3.  [11C]PIB in a nondemented population: potential antecedent marker of Alzheimer disease.

Authors:  M A Mintun; G N Larossa; Y I Sheline; C S Dence; S Y Lee; R H Mach; W E Klunk; C A Mathis; S T DeKosky; J C Morris
Journal:  Neurology       Date:  2006-08-08       Impact factor: 9.910

4.  CSF biomarker variability in the Alzheimer's Association quality control program.

Authors:  Niklas Mattsson; Ulf Andreasson; Staffan Persson; Maria C Carrillo; Steven Collins; Sonia Chalbot; Neal Cutler; Diane Dufour-Rainfray; Anne M Fagan; Niels H H Heegaard; Ging-Yuek Robin Hsiung; Bradley Hyman; Khalid Iqbal; Stephan A Kaeser; Stephan A Käser; D Richard Lachno; Alberto Lleó; Piotr Lewczuk; José L Molinuevo; Piero Parchi; Axel Regeniter; Robert A Rissman; Robert Rissman; Hanna Rosenmann; Giuseppe Sancesario; Johannes Schröder; Leslie M Shaw; Charlotte E Teunissen; John Q Trojanowski; Hugo Vanderstichele; Manu Vandijck; Marcel M Verbeek; Henrik Zetterberg; Kaj Blennow
Journal:  Alzheimers Dement       Date:  2013-05       Impact factor: 21.566

5.  Longitudinal Cerebrospinal Fluid Biomarker Changes in Preclinical Alzheimer Disease During Middle Age.

Authors:  Courtney L Sutphen; Mateusz S Jasielec; Aarti R Shah; Elizabeth M Macy; Chengjie Xiong; Andrei G Vlassenko; Tammie L S Benzinger; Erik E J Stoops; Hugo M J Vanderstichele; Britta Brix; Heather D Darby; Manu L J Vandijck; Jack H Ladenson; John C Morris; David M Holtzman; Anne M Fagan
Journal:  JAMA Neurol       Date:  2015-09       Impact factor: 18.302

Review 6.  Pre-analytical and analytical factors influencing Alzheimer's disease cerebrospinal fluid biomarker variability.

Authors:  Anthony Fourier; Erik Portelius; Henrik Zetterberg; Kaj Blennow; Isabelle Quadrio; Armand Perret-Liaudet
Journal:  Clin Chim Acta       Date:  2015-06-30       Impact factor: 3.786

7.  Partial volume correction in quantitative amyloid imaging.

Authors:  Yi Su; Tyler M Blazey; Abraham Z Snyder; Marcus E Raichle; Daniel S Marcus; Beau M Ances; Randall J Bateman; Nigel J Cairns; Patricia Aldea; Lisa Cash; Jon J Christensen; Karl Friedrichsen; Russ C Hornbeck; Angela M Farrar; Christopher J Owen; Richard Mayeux; Adam M Brickman; William Klunk; Julie C Price; Paul M Thompson; Bernadino Ghetti; Andrew J Saykin; Reisa A Sperling; Keith A Johnson; Peter R Schofield; Virginia Buckles; John C Morris; Tammie L S Benzinger
Journal:  Neuroimage       Date:  2014-12-05       Impact factor: 6.556

Review 8.  Reference measurement procedures for Alzheimer's disease cerebrospinal fluid biomarkers: definitions and approaches with focus on amyloid β42.

Authors:  Niklas Mattsson; Ingrid Zegers; Ulf Andreasson; Maria Bjerke; Marinus A Blankenstein; Robert Bowser; Maria C Carrillo; Johan Gobom; Theresa Heath; Rand Jenkins; Andreas Jeromin; June Kaplow; Daniel Kidd; Omar F Laterza; Andrew Lockhart; Michael P Lunn; Robert L Martone; Kevin Mills; Josef Pannee; Marianne Ratcliffe; Leslie M Shaw; Adam J Simon; Holly Soares; Charlotte E Teunissen; Marcel M Verbeek; Robert M Umek; Hugo Vanderstichele; Henrik Zetterberg; Kaj Blennow; Erik Portelius
Journal:  Biomark Med       Date:  2012-08       Impact factor: 2.851

9.  Longitudinal change in CSF biomarkers in autosomal-dominant Alzheimer's disease.

Authors:  Anne M Fagan; Chengjie Xiong; Mateusz S Jasielec; Randall J Bateman; Alison M Goate; Tammie L S Benzinger; Bernardino Ghetti; Ralph N Martins; Colin L Masters; Richard Mayeux; John M Ringman; Martin N Rossor; Stephen Salloway; Peter R Schofield; Reisa A Sperling; Daniel Marcus; Nigel J Cairns; Virginia D Buckles; Jack H Ladenson; John C Morris; David M Holtzman
Journal:  Sci Transl Med       Date:  2014-03-05       Impact factor: 17.956

Review 10.  Biomarkers for Alzheimer's disease therapeutic trials.

Authors:  Harald Hampel; Gordon Wilcock; Sandrine Andrieu; Paul Aisen; Kaj Blennow; K Broich; Maria Carrillo; Nick C Fox; Giovanni B Frisoni; Maria Isaac; Simon Lovestone; Agneta Nordberg; David Prvulovic; Christina Sampaio; Philip Scheltens; Michael Weiner; Bengt Winblad; Nicola Coley; Bruno Vellas
Journal:  Prog Neurobiol       Date:  2010-12-02       Impact factor: 11.685

View more
  24 in total

1.  Depression and Alzheimer's Disease Biomarkers Predict Driving Decline.

Authors:  Ganesh M Babulal; Suzie Chen; Monique M Williams; Jean-Francois Trani; Parul Bakhshi; Grace L Chao; Sarah H Stout; Anne M Fagan; Tammie L S Benzinger; David M Holtzman; John C Morris; Catherine M Roe
Journal:  J Alzheimers Dis       Date:  2018       Impact factor: 4.472

2.  Incident cognitive impairment: longitudinal changes in molecular, structural and cognitive biomarkers.

Authors:  Catherine M Roe; Beau M Ances; Denise Head; Ganesh M Babulal; Sarah H Stout; Elizabeth A Grant; Jason Hassenstab; Chengjie Xiong; David M Holtzman; Tammie L S Benzinger; Suzanne E Schindler; Anne M Fagan; John C Morris
Journal:  Brain       Date:  2018-11-01       Impact factor: 13.501

3.  Developing a Spatial Navigation Screening Tool Sensitive to the Preclinical Alzheimer Disease Continuum.

Authors:  Samantha L Allison; Thomas L Rodebaugh; Chiharu Johnston; Anne M Fagan; John C Morris; Denise Head
Journal:  Arch Clin Neuropsychol       Date:  2019-10-24       Impact factor: 2.813

4.  Alzheimer Disease Biomarkers and Driving in Clinically Normal Older Adults: Role of Spatial Navigation Abilities.

Authors:  Samantha Allison; Ganesh M Babulal; Sarah H Stout; Peggy P Barco; David B Carr; Anne M Fagan; John C Morris; Catherine M Roe; Denise Head
Journal:  Alzheimer Dis Assoc Disord       Date:  2018 Apr-Jun       Impact factor: 2.703

5.  Cerebrospinal fluid biomarkers measured by Elecsys assays compared to amyloid imaging.

Authors:  Suzanne E Schindler; Julia D Gray; Brian A Gordon; Chengjie Xiong; Richard Batrla-Utermann; Marian Quan; Simone Wahl; Tammie L S Benzinger; David M Holtzman; John C Morris; Anne M Fagan
Journal:  Alzheimers Dement       Date:  2018-03-02       Impact factor: 21.566

6.  Differences in Driving Outcomes Among Cognitively Normal African American and Caucasian Older Adults.

Authors:  Ganesh M Babulal; Sarah H Stout; Monique M Williams; Ganesh Rajasekar; Annie Harmon; Jonathon Vivoda; Megan Zuelsdorff; Tammie L S Benzinger; John C Morris; Beau Ances; Catherine M Roe
Journal:  J Racial Ethn Health Disparities       Date:  2019-11-04

7.  Interpreting Biomarker Results in Individual Patients With Mild Cognitive Impairment in the Alzheimer's Biomarkers in Daily Practice (ABIDE) Project.

Authors:  Ingrid S van Maurik; Marissa D Zwan; Betty M Tijms; Femke H Bouwman; Charlotte E Teunissen; Philip Scheltens; Mike P Wattjes; Frederik Barkhof; Johannes Berkhof; Wiesje M van der Flier
Journal:  JAMA Neurol       Date:  2017-12-01       Impact factor: 18.302

8.  Assessment of Racial Disparities in Biomarkers for Alzheimer Disease.

Authors:  John C Morris; Suzanne E Schindler; Lena M McCue; Krista L Moulder; Tammie L S Benzinger; Carlos Cruchaga; Anne M Fagan; Elizabeth Grant; Brian A Gordon; David M Holtzman; Chengjie Xiong
Journal:  JAMA Neurol       Date:  2019-03-01       Impact factor: 18.302

9.  Obstructive sleep apnea treatment, slow wave activity, and amyloid-β.

Authors:  Yo-El S Ju; Margaret A Zangrilli; Mary Beth Finn; Anne M Fagan; David M Holtzman
Journal:  Ann Neurol       Date:  2019-01-17       Impact factor: 10.422

10.  Obesity and White Matter Neuroinflammation Related Edema in Alzheimer's Disease Dementia Biomarker Negative Cognitively Normal Individuals.

Authors:  Maria Ly; Cyrus A Raji; Gary Z Yu; Qing Wang; Yong Wang; Suzanne E Schindler; Hongyu An; Amjad Samara; Sarah A Eisenstein; Tamara Hershey; Gordon Smith; Samuel Klein; Jingxia Liu; Chengjie Xiong; Beau M Ances; John C Morris; Tammie L S Benzinger
Journal:  J Alzheimers Dis       Date:  2021       Impact factor: 4.472

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.